Antithrombotic therapy represents the mainstay of the pharmacological treatment in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) [1]. Dual antiplatelet therapy (DAPT), consisting of aspirin and a P2Y12 inhibitor, is generally recommended for 6 or 12 months in patients with chronic coronary syndromes (CCS) or acute coronary syndromes (ACS) [2,3], respectively. This recommendation stems from previous studies which, more than 20 years ago, showed an increased risk of thrombotic complications after PCI.
